$FRSX
Foresight Autonomous Holdings Ltd. Stock $frsx

$frsx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000149315224011506 Filed on March 27, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$138.0K	$497.0K	$99.00K
YoY Change	39.39%	-9.64%	23.75%
Cost Of Revenue	$39.00K	$143.0K	$44.00K
YoY Change	-11.36%	-43.25%	37.5%
Gross Profit	$99.00K	$354.0K	$55.00K
YoY Change	80.0%	18.79%	14.58%
Gross Profit Margin	71.74%	71.23%	55.56%
Selling, General & Admin	$965.0K	$5.058M	$1.558M
YoY Change	-38.06%	-18.67%	2.7%
% of Gross Profit	974.75%	1428.81%	2832.73%
Research & Development	$2.432M	$11.59M	$3.035M
YoY Change	-19.87%	0.46%	14.66%
% of Gross Profit	2456.57%	3273.16%	5518.18%
Depreciation & Amortization	$74.00K	$263.0K	$57.00K
YoY Change	29.82%	20.64%	42.5%
% of Gross Profit	74.75%	74.29%	103.64%
Operating Expenses	$3.397M	$16.65M	$4.593M
YoY Change	-26.04%	-6.24%	10.3%
Operating Profit	-$3.298M	-$16.29M	-$4.538M
YoY Change	-27.32%	-6.67%	10.25%
Interest Expense	-$255.0K	-$2.320M	$718.0K
YoY Change	-135.52%	5.07%	84.1%
% of Operating Profit
Other Income/Expense, Net		$201.0K
YoY Change		-104.76%
Pretax Income	-$3.553M	-$18.41M	-$3.820M
YoY Change	-6.99%	-15.07%	2.52%
Income Tax
% Of Pretax Income
Net Earnings	-$3.553M	-$18.41M	-$3.820M
YoY Change	-6.99%	-15.07%	2.52%
Net Earnings / Revenue	-2574.64%	-3704.23%	-3858.59%
Basic Earnings Per Share		-$0.06
Diluted Earnings Per Share	-$0.01	-$0.06	-$0.01
COMMON SHARES
Basic Shares Outstanding	459.8M shares	331.4M shares	323.0M shares
Diluted Shares Outstanding		331.4M shares

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.11M	$16.11M	$26.39M
YoY Change	-38.96%	-38.96%	-42.27%
Cash & Equivalents	$15.64M	$15.64M	$19.17M
Short-Term Investments	$474.0K	$474.0K	$7.218M
Other Short-Term Assets	$99.00K	$246.0K	$102.0K
YoY Change	-2.94%	-48.96%
Inventory
Prepaid Expenses	$147.0K		$380.0K
Receivables	$308.0K	$308.0K
Other Receivables	$531.0K	$384.0K	$842.0K
Total Short-Term Assets	$17.05M	$17.05M	$27.34M
YoY Change	-37.64%	-37.64%	-41.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.263M	$2.263M	$598.0K
YoY Change	278.43%	-17.83%	-80.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$2.804M
YoY Change	-100.0%	-100.0%	-30.09%
Other Assets
YoY Change
Total Long-Term Assets	$2.263M	$2.263M	$5.558M
YoY Change	-59.28%	-59.28%	-21.81%
TOTAL ASSETS
Total Short-Term Assets	$17.05M	$17.05M	$27.34M
Total Long-Term Assets	$2.263M	$2.263M	$5.558M
Total Assets	$19.31M	$19.31M	$32.89M
YoY Change	-41.29%	-41.29%	-38.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.684M	$136.0K	$2.107M
YoY Change	-20.08%	-56.83%	732.81%
Accrued Expenses	$468.0K	$2.016M	$299.0K
YoY Change	56.52%	12.5%	24.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$527.0K
YoY Change			-10.22%
Total Short-Term Liabilities	$2.152M	$2.152M	$2.634M
YoY Change	-18.3%	-18.3%	-2.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.476M
YoY Change	-100.0%	-100.0%	-31.12%
Other Long-Term Liabilities	$1.163M	$1.163M	$1.476M
YoY Change	-21.21%	-21.21%
Total Long-Term Liabilities	$1.163M	$1.163M	$1.476M
YoY Change	-21.21%	-21.21%	-31.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.152M	$2.152M	$2.634M
Total Long-Term Liabilities	$1.163M	$1.163M	$1.476M
Total Liabilities	$3.918M	$3.918M	$4.110M
YoY Change	-4.67%	-14.14%	-19.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$119.9M		-$101.5M
YoY Change	18.14%		27.16%
Common Stock	$0.00		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.39M	$15.39M	$28.33M
YoY Change
Total Liabilities & Shareholders Equity	$19.31M	$19.31M	$32.89M
YoY Change	-41.29%	-41.29%	-38.5%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	-$3.553M	-$18.41M	-$3.820M
YoY Change	-6.99%	-15.07%	2.52%
Depreciation, Depletion And Amortization	$74.00K	$263.0K	$57.00K
YoY Change	29.82%	20.64%	42.5%
Cash From Operating Activities	-$3.593M	-$14.93M	-$3.954M
YoY Change	-9.13%	-12.49%	25.52%
INVESTING ACTIVITIES
Capital Expenditures	$9.000K	$124.0K	$31.00K
YoY Change	-70.97%	-60.38%	-126.5%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$7.216M	$10.53M
YoY Change	-100.0%	-22.38%	-1434.22%
Cash From Investing Activities	-$9.000K	$7.092M	$10.50M
YoY Change	-100.09%	-21.05%	-1258.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$4.044M	$4.181M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.044M	4.181M	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-3.593M	-14.93M	-3.954M
Cash From Investing Activities	-9.000K	7.092M	10.50M
Cash From Financing Activities	4.044M	4.181M	0.000
Net Change In Cash	442.0K	-3.653M	6.542M
YoY Change	-93.24%	-59.01%	-261.29%
FREE CASH FLOW
Cash From Operating Activities	-$3.593M	-$14.93M	-$3.954M
Capital Expenditures	$9.000K	$124.0K	$31.00K
Free Cash Flow	-$3.602M	-$15.05M	-$3.985M
YoY Change	-9.61%	-13.36%	31.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001691221
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent		usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2023Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent		usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2023	FRSX	Investment In Simple Agreement For Future Equity InvestmentInSimpleAgreementForFutureEquity		usd
CY2021	FRSX	Investment In Simple Agreement For Future Equity InvestmentInSimpleAgreementForFutureEquity		usd
CY2023	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi		usd
CY2021	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables		usd
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables		usd
CY2022	FRSX	Accrued Issuance Costs Recorded In Shareholders Equity AccruedIssuanceCostsRecordedInShareholdersEquity		usd
CY2021	FRSX	Accrued Issuance Costs Recorded In Shareholders Equity AccruedIssuanceCostsRecordedInShareholdersEquity		usd
CY2023	FRSX	Conversion Of Simple Agreement For Future Equity To Investment In Equity Securities ConversionOfSimpleAgreementForFutureEquityToInvestmentInEquitySecurities		usd
CY2021	FRSX	Conversion Of Simple Agreement For Future Equity To Investment In Equity Securities ConversionOfSimpleAgreementForFutureEquityToInvestmentInEquitySecurities		usd
CY2022	FRSX	New Operating Lease Assets Obtained In Exchange For Operating Lease Liabilities NewOperatingLeaseAssetsObtainedInExchangeForOperatingLeaseLiabilities		usd
CY2023	FRSX	Sales Of Prototypes SalesOfPrototypes		usd
CY2022	FRSX	Sales Of Prototypes SalesOfPrototypes		usd
CY2021	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38094
CY2023	dei	Entity Registrant Name EntityRegistrantName	FORESIGHT AUTONOMOUS HOLDINGS LTD.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	7 Golda Meir
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Ness Ziona
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	7403650
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023	dei	Security12b Title Security12bTitle	American Depositary Shares each representing 30 Ordinary Shares, no par value
CY2023	dei	Trading Symbol TradingSymbol	FRSX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	459778056	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	1197
CY2023	dei	Auditor Name AuditorName	Brightman Almagor Zohar & Co
CY2023	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15635000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19173000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	99000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	102000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	7216000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	474000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	308000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	531000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	842000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	17047000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	27335000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1802000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2156000	usd
CY2022Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	2804000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	461000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	598000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	2263000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	5558000	usd
CY2023Q4	us-gaap	Assets Assets	19310000	usd
CY2022Q4	us-gaap	Assets Assets	32893000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	136000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	315000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	468000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	527000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1548000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1792000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2152000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2634000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1163000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1476000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3315000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4110000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	459778056	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	459778056	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	322979556	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	322979556	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	135282000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	129810000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-119890000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101480000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	15392000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	28330000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	603000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	453000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15995000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28783000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19310000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32893000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	497000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	550000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	120000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	143000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	252000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	67000	usd
CY2023	us-gaap	Gross Profit GrossProfit	354000	usd
CY2022	us-gaap	Gross Profit GrossProfit	298000	usd
CY2021	us-gaap	Gross Profit GrossProfit	53000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11587000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11534000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10170000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1939000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2230000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1848000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3119000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3989000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3980000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-16291000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-17455000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-15945000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2119000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4221000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	909000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-18410000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-21676000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15036000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	331350000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	331350000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	322817000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	322817000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	321356000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	321356000	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	47045000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13508000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	57000	usd
CY2021	FRSX	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	595000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2464000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15036000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	48633000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1822000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-21676000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28783000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28783000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4181000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1441000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-18410000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15995000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15995000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	485000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	465000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-18410000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-21676000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15036000	usd
CY2023	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	3484000	usd
CY2022	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	4619000	usd
CY2021	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	2911000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14926000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17057000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12125000	usd
CY2023	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-7216000	usd
CY2022	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-10297000	usd
CY2021	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	12347000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	124000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	313000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	235000	usd
CY2022	FRSX	Investment In Simple Agreement For Future Equity InvestmentInSimpleAgreementForFutureEquity	286000	usd
CY2022	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	715000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7092000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8983000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12582000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4181000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13508000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	595000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	57000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4181000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14160000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	112000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-839000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-37000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3541000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8913000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10584000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19275000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28188000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38772000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15734000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19275000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28188000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1441000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1826000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2464000	usd
CY2023	us-gaap	Depreciation Depreciation	263000	usd
CY2022	us-gaap	Depreciation Depreciation	218000	usd
CY2021	us-gaap	Depreciation Depreciation	159000	usd
CY2023	FRSX	Revaluation Of Marketable Securities RevaluationOfMarketableSecurities	2330000	usd
CY2022	FRSX	Revaluation Of Marketable Securities RevaluationOfMarketableSecurities	2217000	usd
CY2021	FRSX	Revaluation Of Marketable Securities RevaluationOfMarketableSecurities	30000	usd
CY2023	FRSX	Exchange Rate Changes On Cash And Cash Equivalents ExchangeRateChangesOnCashAndCashEquivalents	-112000	usd
CY2022	FRSX	Exchange Rate Changes On Cash And Cash Equivalents ExchangeRateChangesOnCashAndCashEquivalents	839000	usd
CY2021	FRSX	Exchange Rate Changes On Cash And Cash Equivalents ExchangeRateChangesOnCashAndCashEquivalents	37000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-311000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	182000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	259000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-179000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	62000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-138000	usd
CY2023	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	308000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-18000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-289000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-33000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-244000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-72000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	651000	usd
CY2023	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	3484000	usd
CY2022	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	4619000	usd
CY2021	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	2911000	usd
CY2023	FRSX	Accrued Issuance Costs Recorded In Shareholders Equity AccruedIssuanceCostsRecordedInShareholdersEquity	92000	usd
CY2022	FRSX	Conversion Of Simple Agreement For Future Equity To Investment In Equity Securities ConversionOfSimpleAgreementForFutureEquityToInvestmentInEquitySecurities	286000	usd
CY2023	FRSX	American Depository Shares Description AmericanDepositorySharesDescription	The ADSs are listed on The Nasdaq Capital Market, and the ratio of the Company’s Ordinary Shares to ADSs is 30:1
CY2016Q1	FRSX	Ordinary Shares Issued Percentage OrdinarySharesIssuedPercentage	0.6450	pure
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-18410000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-21676000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zWYYFc6NJHQ6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_zxewZ0PzJCqg">Use of estimates in the preparation of financial statements:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company’s management believes that the estimates, judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect reported amounts and disclosures made. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15036000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2023	FRSX	Earnings Per Share Basic American Depository Shares EarningsPerShareBasicAmericanDepositoryShares	-1.8
CY2023	FRSX	Earnings Per Share Diluted American Depository Shares EarningsPerShareDilutedAmericanDepositoryShares	-1.8
CY2022	FRSX	Earnings Per Share Basic American Depository Shares EarningsPerShareBasicAmericanDepositoryShares	-2.1
CY2022	FRSX	Earnings Per Share Diluted American Depository Shares EarningsPerShareDilutedAmericanDepositoryShares	-2.1
CY2021	FRSX	Earnings Per Share Basic American Depository Shares EarningsPerShareBasicAmericanDepositoryShares	-1.5
CY2021	FRSX	Earnings Per Share Diluted American Depository Shares EarningsPerShareDilutedAmericanDepositoryShares	-1.5
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	331350000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	331350000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	322817000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	322817000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	321356000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	321356000	shares
CY2023	FRSX	Weighted Average Number Of Share Outstanding Basic In American Depository Shares WeightedAverageNumberOfShareOutstandingBasicInAmericanDepositoryShares	11045000	shares
CY2023	FRSX	Weighted Average Number Of Share Outstanding Diluted In American Depository Shares WeightedAverageNumberOfShareOutstandingDilutedInAmericanDepositoryShares	11045000	shares
CY2022	FRSX	Weighted Average Number Of Share Outstanding Basic In American Depository Shares WeightedAverageNumberOfShareOutstandingBasicInAmericanDepositoryShares	10761000	shares
CY2022	FRSX	Weighted Average Number Of Share Outstanding Diluted In American Depository Shares WeightedAverageNumberOfShareOutstandingDilutedInAmericanDepositoryShares	10761000	shares
CY2021	FRSX	Weighted Average Number Of Share Outstanding Basic In American Depository Shares WeightedAverageNumberOfShareOutstandingBasicInAmericanDepositoryShares	10712000	shares
CY2021	FRSX	Weighted Average Number Of Share Outstanding Diluted In American Depository Shares WeightedAverageNumberOfShareOutstandingDilutedInAmericanDepositoryShares	10712000	shares
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	4011000	usd
CY2022	FRSX	Revaluation To Fair Value Through Profit Or Loss RevaluationToFairValueThroughProfitOrLoss	-2208000	usd
CY2022	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	715000	usd
CY2022	FRSX	Conversion Of Simple Agreement For Future Equity To Investment In Equity Securities ConversionOfSimpleAgreementForFutureEquityToInvestmentInEquitySecurities	286000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	2804000	usd
CY2023	FRSX	Revaluation To Fair Value Through Profit Or Loss RevaluationToFairValueThroughProfitOrLoss	-2333000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	471000	usd
CY2023Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	224000	usd
CY2022Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	225000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	147000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	380000	usd
CY2023Q4	FRSX	Grants Receivable Other GrantsReceivableOther	134000	usd
CY2022Q4	FRSX	Grants Receivable Other GrantsReceivableOther	117000	usd
CY2023Q4	FRSX	Other Receivable OtherReceivable	26000	usd
CY2022Q4	FRSX	Other Receivable OtherReceivable	120000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	531000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	842000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1778000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1674000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1317000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1076000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	461000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	598000	usd
CY2023	us-gaap	Depreciation Depreciation	263000	usd
CY2022	us-gaap	Depreciation Depreciation	218000	usd
CY2023	us-gaap	General Discussion Of Pension And Other Postretirement Benefits GeneralDiscussionOfPensionAndOtherPostretirementBenefits	Pursuant to section 14 of the Israeli Severance Pay Law, 5723-1963, the Company’s employees covered under this section are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with pension companies.
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1098	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1065	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	876	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1385000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1493000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	163000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	299000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1548000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1792000	usd
CY2023Q4	us-gaap	Decommissioning Fund Investments DecommissioningFundInvestments	5000000	usd
CY2023	FRSX	Royalty Description RoyaltyDescription	Magna obtained grants from the Israeli Innovation Authority (the “IIA”) for participation in research and development programs for the years 2011 through 2013, and, in return, further to an acquisition transaction between the Company and Magna, the Company is obligated to pay royalties amounting to 3% to 5% of its future sales up to the amount of the grant.
CY2023Q4	us-gaap	Grants Receivable GrantsReceivable	620000	usd
CY2022Q4	us-gaap	Grants Receivable GrantsReceivable	603000	usd
CY2023	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company and its subsidiaries, Foresight Ltd. and Eye Net, currently have 3-year leases for their offices with options to extend the leases for another 3 years. The lease for Foresight Ltd. and Eye Net ends on March 31, 2027, and December 15, 2027, respectively. The Company also currently leases several vehicles, each for a term of 3 years. The Company has no finance leases.
CY2023	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	options to extend the leases for another 3 years.
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	537000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	550000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	460000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	562000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	588000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	480000	usd
CY2023	FRSX	New Operating Lease Assets Obtained In Exchange For Operating Lease Liabilities NewOperatingLeaseAssetsObtainedInExchangeForOperatingLeaseLiabilities	154000	usd
CY2021	FRSX	New Operating Lease Assets Obtained In Exchange For Operating Lease Liabilities NewOperatingLeaseAssetsObtainedInExchangeForOperatingLeaseLiabilities	1824000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	536000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	520000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	482000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	211000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1749000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	118000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1631000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	939000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1441000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1826000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2464000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	150000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	225000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	154000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1291000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1601000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2310000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	497000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	550000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	120000	usd
CY2023	FRSX	Payroll Research And Development Related Expenses PayrollResearchAndDevelopmentRelatedExpenses	8997000	usd
CY2022	FRSX	Payroll Research And Development Related Expenses PayrollResearchAndDevelopmentRelatedExpenses	8778000	usd
CY2021	FRSX	Payroll Research And Development Related Expenses PayrollResearchAndDevelopmentRelatedExpenses	7556000	usd
CY2023	FRSX	Subcontracted Work And Consulting Fee Expenses Related To Research And Development SubcontractedWorkAndConsultingFeeExpensesRelatedToResearchAndDevelopment	1229000	usd
CY2022	FRSX	Subcontracted Work And Consulting Fee Expenses Related To Research And Development SubcontractedWorkAndConsultingFeeExpensesRelatedToResearchAndDevelopment	1523000	usd
CY2021	FRSX	Subcontracted Work And Consulting Fee Expenses Related To Research And Development SubcontractedWorkAndConsultingFeeExpensesRelatedToResearchAndDevelopment	1751000	usd
CY2023	FRSX	Share Based Payments To Service Provider Related To Research And Development ShareBasedPaymentsToServiceProviderRelatedToResearchAndDevelopment	19000	usd
CY2022	FRSX	Share Based Payments To Service Provider Related To Research And Development ShareBasedPaymentsToServiceProviderRelatedToResearchAndDevelopment	57000	usd
CY2021	FRSX	Share Based Payments To Service Provider Related To Research And Development ShareBasedPaymentsToServiceProviderRelatedToResearchAndDevelopment	118000	usd
CY2023	FRSX	Rent And Office Maintenance For Research And Development RentAndOfficeMaintenanceForResearchAndDevelopment	936000	usd
CY2022	FRSX	Rent And Office Maintenance For Research And Development RentAndOfficeMaintenanceForResearchAndDevelopment	1068000	usd
CY2021	FRSX	Rent And Office Maintenance For Research And Development RentAndOfficeMaintenanceForResearchAndDevelopment	810000	usd
CY2023	FRSX	Travel Expenses Related To Research And Development TravelExpensesRelatedToResearchAndDevelopment	90000	usd
CY2022	FRSX	Travel Expenses Related To Research And Development TravelExpensesRelatedToResearchAndDevelopment	141000	usd
CY2021	FRSX	Travel Expenses Related To Research And Development TravelExpensesRelatedToResearchAndDevelopment	44000	usd
CY2023	FRSX	Other Research And Development OtherResearchAndDevelopment	416000	usd
CY2022	FRSX	Other Research And Development OtherResearchAndDevelopment	362000	usd
CY2021	FRSX	Other Research And Development OtherResearchAndDevelopment	309000	usd
CY2023	FRSX	Less Participation In Grants Researchand Development Total LessParticipationInGrantsResearchandDevelopmentTotal	-100000	usd
CY2022	FRSX	Less Participation In Grants Researchand Development Total LessParticipationInGrantsResearchandDevelopmentTotal	-395000	usd
CY2021	FRSX	Less Participation In Grants Researchand Development Total LessParticipationInGrantsResearchandDevelopmentTotal	-351000	usd
CY2021	FRSX	Sales Of Prototypes SalesOfPrototypes	-67000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11587000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11534000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10170000	usd
CY2023	FRSX	Payroll Marketing And Sales Related Expenses PayrollMarketingAndSalesRelatedExpenses	1076000	usd
CY2022	FRSX	Payroll Marketing And Sales Related Expenses PayrollMarketingAndSalesRelatedExpenses	1318000	usd
CY2021	FRSX	Payroll Marketing And Sales Related Expenses PayrollMarketingAndSalesRelatedExpenses	1273000	usd
CY2023	FRSX	Marketing And Sales Exhibitions Conventions And Travel Expenses MarketingAndSalesExhibitionsConventionsAndTravelExpenses	379000	usd
CY2022	FRSX	Marketing And Sales Exhibitions Conventions And Travel Expenses MarketingAndSalesExhibitionsConventionsAndTravelExpenses	302000	usd
CY2021	FRSX	Marketing And Sales Exhibitions Conventions And Travel Expenses MarketingAndSalesExhibitionsConventionsAndTravelExpenses	42000	usd
CY2023	FRSX	Marketing And Sales Consultants Fees MarketingAndSalesConsultantsFees	416000	usd
CY2022	FRSX	Marketing And Sales Consultants Fees MarketingAndSalesConsultantsFees	558000	usd
CY2021	FRSX	Marketing And Sales Consultants Fees MarketingAndSalesConsultantsFees	394000	usd
CY2023	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	68000	usd
CY2022	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	52000	usd
CY2021	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	139000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1939000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2230000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1848000	usd
CY2023	FRSX	Payroll General And Administrative Related Expenses PayrollGeneralAndAdministrativeRelatedExpenses	1458000	usd
CY2022	FRSX	Payroll General And Administrative Related Expenses PayrollGeneralAndAdministrativeRelatedExpenses	1756000	usd
CY2021	FRSX	Payroll General And Administrative Related Expenses PayrollGeneralAndAdministrativeRelatedExpenses	1748000	usd
CY2023	FRSX	Share Based Payments To Service Providers For General And Administrative Expenses ShareBasedPaymentsToServiceProvidersForGeneralAndAdministrativeExpenses	134000	usd
CY2022	FRSX	Share Based Payments To Service Providers For General And Administrative Expenses ShareBasedPaymentsToServiceProvidersForGeneralAndAdministrativeExpenses	215000	usd
CY2021	FRSX	Share Based Payments To Service Providers For General And Administrative Expenses ShareBasedPaymentsToServiceProvidersForGeneralAndAdministrativeExpenses	268000	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	898000	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	1340000	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	1207000	usd
CY2023	FRSX	Directors Fees And Insurance DirectorsFeesAndInsurance	326000	usd
CY2022	FRSX	Directors Fees And Insurance DirectorsFeesAndInsurance	405000	usd
CY2021	FRSX	Directors Fees And Insurance DirectorsFeesAndInsurance	494000	usd
CY2023	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	15000	usd
CY2022	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	8000	usd
CY2023	FRSX	Rent And Office Maintenance RentAndOfficeMaintenance	196000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16893000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15840000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11887000	usd
CY2022	FRSX	Rent And Office Maintenance RentAndOfficeMaintenance	175000	usd
CY2021	FRSX	Rent And Office Maintenance RentAndOfficeMaintenance	212000	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	92000	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	90000	usd
CY2021	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	51000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3119000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3989000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3980000	usd
CY2023	us-gaap	Gain Loss On Securitization Of Financial Assets GainLossOnSecuritizationOfFinancialAssets	-2320000	usd
CY2022	us-gaap	Gain Loss On Securitization Of Financial Assets GainLossOnSecuritizationOfFinancialAssets	-2208000	usd
CY2021	us-gaap	Gain Loss On Securitization Of Financial Assets GainLossOnSecuritizationOfFinancialAssets	-10000	usd
CY2023	FRSX	Bank Interest Income BankInterestIncome	667000	usd
CY2022	FRSX	Bank Interest Income BankInterestIncome	189000	usd
CY2021	FRSX	Bank Interest Income BankInterestIncome	887000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-456000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2194000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	14000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2119000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4221000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	909000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.23	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.23	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.23	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	73448000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	73448000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	68870000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	51683000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16893000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15840000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11887000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	18410000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	21676000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	15036000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4234000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4985000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3458000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-4234000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-4985000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-3458000	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	452000	usd
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	804000	usd
CY2021	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	941000	usd
CY2023Q4	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	42000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	63000	usd

Files In Submission

Name	View Source	Status
0001493152-24-011506-index-headers.html	Edgar Link	pending
0001493152-24-011506-index.html	Edgar Link	pending
0001493152-24-011506.txt	Edgar Link	pending
0001493152-24-011506-xbrl.zip	Edgar Link	pending
ex12-1.htm	Edgar Link	pending
ex12-2.htm	Edgar Link	pending
ex13-1.htm	Edgar Link	pending
ex13-2.htm	Edgar Link	pending
ex15-1.htm	Edgar Link	pending
ex4-3.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
form20-f.htm	Edgar Link	pending
form20-f_001.jpg	Edgar Link	pending
form20-f_002.jpg	Edgar Link	pending
form20-f_003.jpg	Edgar Link	pending
form20-f_004.jpg	Edgar Link	pending
form20-f_005.jpg	Edgar Link	pending
form20-f_006.jpg	Edgar Link	pending
form20-f_007.jpg	Edgar Link	pending
form20-f_008.jpg	Edgar Link	pending
form20-f_009.jpg	Edgar Link	pending
form20-f_010.jpg	Edgar Link	pending
frsx-20231231.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form20-f_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
frsx-20231231_def.xml	Edgar Link	unprocessable
frsx-20231231_lab.xml	Edgar Link	unprocessable
frsx-20231231_pre.xml	Edgar Link	unprocessable
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
frsx-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FRSX
Foresight Autonomous Holdings Ltd. Stock $frsx

2023 Q4 Form 20-F Financial Statement

#000149315224011506 Filed on March 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FRSX Foresight Autonomous Holdings Ltd. Stock $frsx

2023 Q4 Form 20-F Financial Statement

#000149315224011506 Filed on March 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FRSX
Foresight Autonomous Holdings Ltd. Stock $frsx